

State of Oklahoma SoonerCare



Carvykti[™] (ciltacabtagene autoleucel) Prior Authorization Form

	Member Name:	Date of Birth:	Member ID#:	
Billing Provider Information Provider NPI:	Drug Information			
Provider NPI:	Physician billing (H	CPCS code: Start Date	te:	
Provider Phone:	Billing Provider Information			
Prescriber NPI:	Provider NPI: Provider Name:			
Prescriber NPI:	Provider Phone: Provider Fax:			
Prescriber Phone: Prescriber Fax: Specialty: Criteria For Authorization: 1. Please include the most recent office visit note or clinical summary from the hospital to support your request. Is this information attached? Yes No \ 2. Is the health care facility on the certified list to administer chimeric antigen receptor (CAR) T-cells? Yes No \ 3. Is the health care facility trained in the management of cytokine release syndrome (CRS) and neurologic toxicities? Yes No \ 4. Will the health care facility comply with the Carvykti risk evaluation and mitigation strategy (REMS) program requirements? Yes No \ 5. Please indicate the diagnosis and information: Multiple Myeloma A. Is disease status relapsed or refractory? Yes No \ B. Has member received ≥1 line of prior therapy including an immunomodulatory agent and a proteasome inhibitor Yes \ No \ D. Please list therapies member has tried and failed: i. For the therapies listed, did the member undergo at least 2 consecutive cycles of treatment for each regimen? Yes \ No \ 1. If no, please list therapies member received for less than 2 consecutive cycles: a. Was progressive disease seen after 1 cycle of each of these therapies? Yes \ No \ E. Does the member have measurable disease as evidenced by at least 1 of the following? Yes \ No \ Please check all that apply: \[\] \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \				
For Authorization: 1. Please include the most recent office visit note or clinical summary from the hospital to support your request. Is this information attached? Yes No 2. Is the health care facility on the certified list to administer chimeric antigen receptor (CAR) T-cells? Yes No 3. Is the health care facility trained in the management of cytokine release syndrome (CRS) and neurologic toxicities? Yes No 4. Will the health care facility comply with the Carvykti sisk evaluation and mitigation strategy (REMS) program requirements? Yes No 1. So disease status relapsed or refractory? Yes No 1. So disease status relapsed or refractory? Yes No 1. So disease status relapsed or refractory? Yes No 1. Is member received ≥1 line of prior therapy including an immunomodulatory agent and a proteasome inhibitor Yes No 1. No 1. Please list therapies member has tried and failed: I for the therapies listed, did the member undergo at least 2 consecutive cycles of treatment for each regimen? Yes No 1. If no, please list therapies member received for less than 2 consecutive cycles: a. Was progressive disease seen after 1 cycle of each of these therapies? Yes No Please check all that apply: 2. Urine M-protein ≥200mg/24hr Bone marrow plasma cells >30% of total bone marrow cells Serum M-protein ≥200mg/24hr Serum free light chain (FLC) assay: involved FLC ≥10mg/dL (100mg, F. Does the member have central nervous system involvement with multiple myeloma? Yes No	Prescriber NPI:	Prescriber Name:		
For Authorization: 1. Please include the most recent office visit note or clinical summary from the hospital to support your request. Is this information attached? Yes No 2. Is the health care facility on the certified list to administer chimeric antigen receptor (CAR) T-cells? Yes No 3. Is the health care facility trained in the management of cytokine release syndrome (CRS) and neurologic toxicities? Yes No 4. Will the health care facility comply with the Carvykti isk evaluation and mitigation strategy (REMS) program requirements? Yes No 4. Is disease status relapsed or refractory? Yes No 8. Is disease status relapsed or refractory? Yes No 8. Has member received ≥1 line of prior therapy including an immunomodulatory agent and a proteasome inhibitor Yes No 1. Is member refractory to lenalidomide? Yes No 1. Is member refractory to lenalidomide? Yes No 1. If no, please list therapies member has tried and failed: i. For the therapies listed, did the member undergo at least 2 consecutive cycles of treatment for each regimen? Yes No 1. If no, please list therapies member received for less than 2 consecutive cycles: a. Was progressive disease seen after 1 cycle of each of these therapies? Yes No Please check all that apply: 2. Does the member have measurable disease as evidenced by at least 1 of the following? Yes No Please check all that apply: 3. Urrine M-protein ≥200mg/24hr Bone marrow plasma cells >30% of total bone marrow cells Serum M-protein ≥200mg/24hr Serum free light chain (FLC) assay: involved FLC ≥10mg/dL (100mg, F. Does the member have central nervous system involvement with multiple myeloma? Yes No	Prescriber Phone:_	Prescriber Fax:	Specialty:	
1. Please include the most recent office visit note or clinical summary from the hospital to support your request. Is this information attached? Yes No		Criteria		
··	1. Please include the information attached information attached 2. Is the health care of the second	acility on the certified list to administer chimeric ant facility trained in the management of cytokine release of facility trained in the management of cytokine release of facility comply with the Carvykti risk evaluation as estation and information: The diagnosis and information:	tigen receptor (CAR) T-cells? Yes No se syndrome (CRS) and neurologic toxicities? and mitigation strategy (REMS) program mmunomodulatory agent and a proteasome inhibitor vertical to 2 consecutive cycles of treatment for each vertical to 4 to 5 than 2 consecutive cycles: f each of these therapies? Yes No No to 4 the following? Yes No vertical to 5 thain (FLC) assay: involved FLC ≥10mg/dL (100mg/L to 5 the full to 5 the full to 6 the full to 6 the full to 7 the full to 7 the full to 8 the f	

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requesteddata must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.